'The importance of building a strong IP portfolio - a guide for life sciences R&D leaders'

Our first C-Suite breakfast discussion of 2024 takes place at the offices of Venner Shipley in London on 31 January, and will feature a guide for life sciences R&D CEO's on the importance of building a strong IP portfolio.

Discussions on the day will share insight for growing life sciences R&D companies on the importance of building an IP portfolio in advance of interactions with investors, big pharma and other industry partners and the importance of working with trusted advisors and experts who understand what the requirements of future partners may be.

This session will feature introductory presentations from the team at Venner Shipley who will share details of the types of intellectual property protection, pros and cons of registration, as well commercial and financial risks. We will also hear a case-study from an R&D leader about their IP journey, before opening the floor up to a moderated round table discussion on this incredibly important topic.

Programme:

08.30 - 09.00 Guest arrival and breakfast served

09.00 - 09.30 Introductions & keynotes from:

• Kirsty Dolphin, Partner, Director of Renewals, Patent Attorney, Venner Shipley ​
• Anton Hutter, Partner, Patent Attorney, Venner Shipley​
• Simon Chandler, CEO, Rinri Therapeutics ​

09.30 - 10.30 Round table discussion with all guests and speakers, facilitated by OBN

OBN's round table C-Suite Discussions are designed exclusively for senior leaders (C-Suite or equivalent) from life sciences organisations, whether R&D or those involved in providing critical support services to the industry. The purpose of these events is to generate some interesting, useful, high-level and boundary pushing discussion and debate, that creates some practical thought-leadership output.